CA3218550A1 - Dosing regimens - Google Patents

Dosing regimens Download PDF

Info

Publication number
CA3218550A1
CA3218550A1 CA3218550A CA3218550A CA3218550A1 CA 3218550 A1 CA3218550 A1 CA 3218550A1 CA 3218550 A CA3218550 A CA 3218550A CA 3218550 A CA3218550 A CA 3218550A CA 3218550 A1 CA3218550 A1 CA 3218550A1
Authority
CA
Canada
Prior art keywords
asciminib
imatinib
pharmaceutically acceptable
administered
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218550A
Other languages
English (en)
French (fr)
Inventor
Stephanie Kay Dodd
Florence HOURCADE-POTELLERET
Felix Huth
Michelle QUINLAN
Julia ZACK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3218550A1 publication Critical patent/CA3218550A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3218550A 2021-05-11 2022-05-10 Dosing regimens Pending CA3218550A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187023P 2021-05-11 2021-05-11
US63/187,023 2021-05-11
PCT/IB2022/054321 WO2022238884A1 (en) 2021-05-11 2022-05-10 Dosing regimens

Publications (1)

Publication Number Publication Date
CA3218550A1 true CA3218550A1 (en) 2022-11-17

Family

ID=81846537

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218550A Pending CA3218550A1 (en) 2021-05-11 2022-05-10 Dosing regimens

Country Status (8)

Country Link
US (1) US20240245666A1 (https=)
EP (1) EP4337205A1 (https=)
JP (1) JP2024518426A (https=)
KR (1) KR20240006600A (https=)
CN (1) CN117396202A (https=)
CA (1) CA3218550A1 (https=)
IL (1) IL308095A (https=)
WO (1) WO2022238884A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120239604A (zh) * 2023-11-01 2025-07-01 深圳市塔吉瑞生物医药有限公司 治疗白血病的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161416A1 (es) * 2012-05-15 2017-01-08 Novartis Ag Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1

Also Published As

Publication number Publication date
CN117396202A (zh) 2024-01-12
EP4337205A1 (en) 2024-03-20
WO2022238884A1 (en) 2022-11-17
US20240245666A1 (en) 2024-07-25
JP2024518426A (ja) 2024-05-01
IL308095A (en) 2023-12-01
KR20240006600A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
US9585893B2 (en) Flumazenil complexes, compositions comprising same and uses thereof
US12036224B2 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
US20160324852A1 (en) Compositions and methods of treating a neurodegenerative disease
US20110070319A1 (en) Bifeprunox doses for treating schizophrenia
JP7754799B2 (ja) てんかん重積状態の治療に使用するためのガナキソロン
CN108472275A (zh) 治疗缺血性中风的组合物及方法
US9750739B2 (en) Orvepitant for chronic cough therapy
US20220323437A1 (en) Methods for treating pulmonary arterial hypertension
EP0730865B1 (en) Use of serotonin and dopamine receptor blockers for the treatment of mental disorders associated with cerebrovascular disease
US20170326141A1 (en) Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
CA3230291A1 (en) Dosing regimens associated with extended release paliperidone injectable formulations
TW200815014A (en) Method of improved diuresis in individuals with impaired renal function
US9700565B2 (en) Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
US20240245666A1 (en) Dosing regimens
US20200253959A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
JP6499634B2 (ja) 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ
BRPI0616659A2 (pt) droga terapÊutica antituberculose, medicamento, e, kit para o tratamento de tuberculose
US20230338349A1 (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
WO2004016268A1 (en) Composition and method for controlling alcohol-induced facial flushing in susceptible humans
JP2835547B2 (ja) 糖尿病治療剤
WO2024023696A1 (en) Dosing regimen for a nlrp3 inhibitor
WO2015191686A1 (en) Methods of administering methylnaltrexone

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241221

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241221

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260421

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260421